FindTrial
Sign In

ONC206

DRUG3 trials

Sponsors

Jazz Pharmaceuticals, Sabine Mueller, MD, PhD

Conditions

Advanced Pheochromocytoma and ParagangliomaAnaplastic AstrocytomaAnaplastic MeningiomaAnaplastic OligodendrogliomaAnaplastic Pleomorphic XanthoastrocytomaAtypical MeningiomaCNS TumorCentral Nervous System Neoplasms

Phase 1

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
RecruitingNCT04541082
Jazz PharmaceuticalsAnaplastic Astrocytoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma +20
Start: 2020-10-26End: 2026-12-31Target: 102Updated: 2025-12-18
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
RecruitingNCT04732065
Sabine Mueller, MD, PhDCentral Nervous System Tumor, CNS Tumor, Diffuse Midline Glioma (DMG) +5
Start: 2021-08-23End: 2027-07-31Target: 208Updated: 2026-03-17

Phase 2

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
RecruitingNCT07282587
Jazz PharmaceuticalsAdvanced Pheochromocytoma and Paraganglioma, PCPG
Start: 2026-01-02End: 2028-12-15Target: 90Updated: 2026-02-27

Related Papers

Abstract PS4-07-19: An agonist of mitochondrial CLPP, ONC206, overcomes mitochondrial dependencies and abates chemoresistance in triple negative breast cancer
Clinical Cancer Research2026-02-17
EXTH-70. ONC206 inhibits tumor growth and is a potential novel therapeutic strategy for refractory medulloblastoma
Neuro-Oncology2025-11-01
Abstract 6400: Preclinical efficacy of combinatorial B7-H3 CAR T cell and ONC206 treatment in DIPG/DMG
Cancer Research2025-04-21
Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT
Oncotarget2025-03-275 citations
Omnigene-Gut<sup>tm</sup> ensures fecal microbiome stability in the pediatric population.
2024-12-06
DIPG-11. PRECLINICAL EFFICACY OF B7-H3 CAR T CELLS IN COMBINATION WITH ONC206
Neuro-Oncology2024-06-18
Co-treatment of human GBM cell lines with imipridone ONC206 and tumor treating fields: Effect on on cell death and p-AKT.
Journal of Clinical Oncology2024-06-01
Abstract 3331: Preclinical combination of ONC206 with radiotherapy and temozolomide in a GBM mouse orthotopic model
Cancer Research2024-03-221 citations
Abstract 3173: Impact of hypoxia on the integrated stress response activated by imipridones ONC201 and ONC206 in pediatric diffuse midline glioma cells
Cancer Research2024-03-22
Abstract 7596: (TTFields) and imipridone ONC206 co-treatment inhibits p-AKT and spheroid growth and upregulates caspase-10 in human GBM cell lines
Cancer Research2024-03-22
Abstract A050: Ferritin, associated with worse overall survival in recurrent GBM, is reduced by combination of HDACi, ONC206 and radiation
Cancer Research2024-03-04
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Cancer Research2023-05-0574 citations
Quantitation of the next-generation imipridone ONC206 in human plasma by a simple and sensitive UPLC-MS/MS assay for clinical pharmacokinetic application.
2022-02-224 citations
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas
Neuro-Oncology2022-02-1191 citations
First-in-human dose escalation and food effect study of oral ONC206 in adults with recurrent primary CNS neoplasms.
Journal of Clinical Oncology2021-05-202 citations